Vaderis Therapeutics AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.vaderis.com
Clinical Trials
3
Active:1
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Assess Safety and Efficacy of VAD044 in HHT Patients
Phase 1
Active, not recruiting
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- Drug: VAD044 Part IDrug: VAD044 Part II
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Vaderis Therapeutics AG
- Target Recruit Count
- 75
- Registration Number
- NCT05406362
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇫🇷Hospices Civils de Lyon, Lyon, France
News
Vaderis' VAD044 Receives FDA Fast Track Designation for Hereditary Hemorrhagic Telangiectasia
Vaderis Therapeutics' VAD044, an allosteric AKT-inhibitor, has been granted Fast Track designation by the FDA for treating Hereditary Hemorrhagic Telangiectasia (HHT).
Vaderis' VAD044 Shows Promise in Hereditary Hemorrhagic Telangiectasia Trial
Vaderis Therapeutics' VAD044 demonstrated favorable safety and tolerability in a Phase 2 proof-of-concept trial for Hereditary Hemorrhagic Telangiectasia (HHT).